Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | O4S.Zn.7H2O |
| Molecular Weight | 287.579 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.O.O.[Zn++].[O-]S([O-])(=O)=O
InChI
InChIKey=RZLVQBNCHSJZPX-UHFFFAOYSA-L
InChI=1S/H2O4S.7H2O.Zn/c1-5(2,3)4;;;;;;;;/h(H2,1,2,3,4);7*1H2;/q;;;;;;;;+2/p-2
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttp://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/https://www.google.com/patents/US3130034http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.t3db.ca/toxins/T3D0733http://www.hmdb.ca/metabolites/HMDB01303Curator's Comment: description was created based on several sources, including
https://www.drugs.com/dosage/zinc-sulfate.html | https://www.ncbi.nlm.nih.gov/pubmed/10721938 | https://www.drugbank.ca/drugs/DB01593 | https://www.ncbi.nlm.nih.gov/pubmed/17132019
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttp://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/https://www.google.com/patents/US3130034http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.t3db.ca/toxins/T3D0733http://www.hmdb.ca/metabolites/HMDB01303
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/dosage/zinc-sulfate.html | https://www.ncbi.nlm.nih.gov/pubmed/10721938 | https://www.drugbank.ca/drugs/DB01593 | https://www.ncbi.nlm.nih.gov/pubmed/17132019
There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.
CNS Activity
Sources: http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicityhttps://www.ncbi.nlm.nih.gov/pubmed/25374537 | https://www.ncbi.nlm.nih.gov/pubmed/15639165https://www.ncbi.nlm.nih.gov/pubmed/2307275https://www.ncbi.nlm.nih.gov/pubmed/10721938
Curator's Comment: Zinc oxide is an amphoteric oxide. It is nearly insoluble in water. Zinc from zinc oxide is, however, slightly absorbed into the skin.
Originator
Sources: http://www.drugdevelopment-technology.com/projects/voraxaze-glucarpidase-for-the-treatment-of-toxic-plasma-methotrexate-concentrations/http://sciencing.com/uses-zinc-carbonate-7889200.htmlhttps://www.webelements.com/zinc/history.html
Curator's Comment: Centuries before zinc was recognized as a distinct element, zinc ores were used for making brass (a mixture of copper and zinc). A brass dating from between 1400-1000 BC has been found in Palestine. An alloy containing 87% zinc was found in prehistoric ruins in Transylvania. The smelting of zinc ores with copper was apparently discovered in Cyprus and was used later by the Romans. Metallic zinc was produced in the 13th century in India by reducing calamine (zinc carbonate, ZnCO3) with organic substances such as wool. The metal was rediscovered later in Europe. William Champion set up a zinc industry in Bristol (England) in the 1740s.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL612426 |
|||
Target ID: GO:0045730 |
|||
Target ID: GO:0006927 |
|||
Target ID: CHEMBL2364710 |
|||
Target ID: ultraviolet B-induced damage |
|||
Target ID: GO:0002456 |
|||
Target ID: Q9NY26 Gene ID: 27173.0 Gene Symbol: SLC39A1 Target Organism: Homo sapiens (Human) |
|||
Target ID: Q9NP94 Gene ID: 29986.0 Gene Symbol: SLC39A2 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Unknown Approved UseUnknown |
|||
| Primary | CORTROPHIN-ZINC Approved UseTreatment of ulcerative colitis and other colonic disorders. Launch Date1955 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Secondary | VORAXAZE Approved UseIndicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate. Launch Date2012 |
|||
| Primary | VUSION Approved UseINDICATIONS AND USAGE
VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when
complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or
budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal
culture for Candida albicans is not adequate evidence of candidal infection since colonization
with C. albicans can result in a positive culture. The presence of candidal infection should be
established by microscopic evaluation prior to initiating treatment.
VUSION Ointment should be used as part of a treatment regimen that includes measures
directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and
frequent diaper changes. Launch Date2006 |
|||
| Primary | ZINC OXIDE Approved UseUnknown |
|||
| Primary | ZINC SULFATE Approved UseUnknown Launch Date1987 |
|||
| Primary | ZINC SULFATE Approved UseUnknown Launch Date1987 |
|||
| Primary | ZINC SULFATE Approved UseUnknown Launch Date1987 |
|||
PubMed
| Title | Date | PubMed |
|---|---|---|
| Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate. | 1991 Apr 1 |
|
| Zinc inhibition of renin and the protease from human immunodeficiency virus type 1. | 1991 Sep 10 |
|
| Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates. | 1993 Aug |
|
| Iron chelators as therapeutic agents against Pneumocystis carinii. | 1994 May |
|
| [Zinc and aluminum concentrations in blood of hemodialysis patients and its impact on the frequency of infections]. | 2005 |
|
| [Reduced thymulin production during occupational exposure to lead]. | 2005 Jan-Mar |
|
| Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality. | 2006 May |
|
| Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats. | 2006 May |
|
| Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. | 2007 May |
|
| Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. | 2007 Nov |
|
| DNA damaging potential of zinc oxide nanoparticles in human epidermal cells. | 2009 Mar 28 |
|
| Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity. | 2010 Dec |
|
| Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles. | 2010 Feb |
|
| Glucarpidase following high-dose methotrexate: update on development. | 2010 Jan |
|
| Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity. | 2011 Jun |
|
| High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue? | 2011 Mar 1 |
|
| Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung. | 2012 Jun 25 |
|
| Glucarpidase for the treatment of life-threatening methotrexate overdose. | 2012 Nov |
|
| Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation. | 2013 Dec |
|
| TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils. | 2013 Jul 31 |
|
| Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells. | 2013 Mar |
|
| Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties. | 2013 Nov 25 |
|
| Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation. | 2013 Sep |
|
| Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation. | 2014 Jul 1 |
|
| Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line. | 2014 Mar 3 |
|
| Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. | 2014 May |
|
| Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function. | 2014 May 15 |
|
| Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity. | 2014 May 16 |
|
| Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition. | 2014 May 16 |
|
| Synthesis aspects, structural, spectroscopic, antimicrobial and room temperature ferromagnetism of zinc iodide complex with Schiff based ligand. | 2015 Jan 25 |
|
| Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction. | 2015 Sep |
|
| Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients. | 2015 Sep |
|
| Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents. | 2016 Oct 1 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
N57JI2K7WP
Created by
admin on Mon Mar 31 18:24:44 GMT 2025 , Edited by admin on Mon Mar 31 18:24:44 GMT 2025
|
PRIMARY | |||
|
DTXSID0040175
Created by
admin on Mon Mar 31 18:24:44 GMT 2025 , Edited by admin on Mon Mar 31 18:24:44 GMT 2025
|
PRIMARY | |||
|
7446-20-0
Created by
admin on Mon Mar 31 18:24:44 GMT 2025 , Edited by admin on Mon Mar 31 18:24:44 GMT 2025
|
PRIMARY | |||
|
N57JI2K7WP
Created by
admin on Mon Mar 31 18:24:44 GMT 2025 , Edited by admin on Mon Mar 31 18:24:44 GMT 2025
|
PRIMARY | |||
|
m11629
Created by
admin on Mon Mar 31 18:24:44 GMT 2025 , Edited by admin on Mon Mar 31 18:24:44 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000087990
Created by
admin on Mon Mar 31 18:24:44 GMT 2025 , Edited by admin on Mon Mar 31 18:24:44 GMT 2025
|
PRIMARY | |||
|
C75659
Created by
admin on Mon Mar 31 18:24:44 GMT 2025 , Edited by admin on Mon Mar 31 18:24:44 GMT 2025
|
PRIMARY | |||
|
62640
Created by
admin on Mon Mar 31 18:24:44 GMT 2025 , Edited by admin on Mon Mar 31 18:24:44 GMT 2025
|
PRIMARY | |||
|
32312
Created by
admin on Mon Mar 31 18:24:44 GMT 2025 , Edited by admin on Mon Mar 31 18:24:44 GMT 2025
|
PRIMARY | |||
|
1311282
Created by
admin on Mon Mar 31 18:24:44 GMT 2025 , Edited by admin on Mon Mar 31 18:24:44 GMT 2025
|
PRIMARY | |||
|
C45678
Created by
admin on Mon Mar 31 18:24:44 GMT 2025 , Edited by admin on Mon Mar 31 18:24:44 GMT 2025
|
CONCEPT | Industrial Aid | ||
|
ZINC SULFATE HEPTAHYDRATE
Created by
admin on Mon Mar 31 18:24:44 GMT 2025 , Edited by admin on Mon Mar 31 18:24:44 GMT 2025
|
PRIMARY | Description: A white or almost white, crystalline powder, or colourless, transparent crystals. Solubility: Very soluble in water, practically insoluble in ethanol (~750 g/l) TS. Category: Adjunct to oral rehydration salts in( prevention and) treatment of dehydration due to diarrhoea; astringent. Storage: Zinc sulfate should be kept in a well-closed, non-metallic container. Labelling: The designation on the container should state whether the substance is in the monohydrate or heptahydrate form and,where appropriate, that it is suitable for use in the manufacture of parenteral dosage forms. Definition: Zinc sulfate monohydrate contains not less than 99.0% and not more than 101.0% of ZnSO4,H2O. Zinc sulfate heptahydrate contains not less than 99.0% and not more than 104.0% of ZnSO4,7H2O. | ||
|
DBSALT001306
Created by
admin on Mon Mar 31 18:24:44 GMT 2025 , Edited by admin on Mon Mar 31 18:24:44 GMT 2025
|
PRIMARY | |||
|
SUB22638
Created by
admin on Mon Mar 31 18:24:44 GMT 2025 , Edited by admin on Mon Mar 31 18:24:44 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
